Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.49 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 11/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5758484 | 0.86 | MCL1 (0.44) | MCL1CYP1A1CYP1A2CYP1B1HSD17B3 | |
| SCHEMBL5865933 | 0.85 | MCL1 (0.51) | MCL1CYP1A1CYP1A2CYP1B1HSD17B3 | |
| SCHEMBL6023766 | 0.85 | MCL1 (0.55) | MCL1CYP1A1CYP1A2CYP1B1HSD17B3 | |
| SCHEMBL6022816 | 0.85 | MCL1 (0.55) | MCL1CYP1A1CYP1A2CYP1B1HSD17B3 | |
| SCHEMBL5865936 | 0.84 | MCL1 (0.54) | MCL1CYP1A1CYP1A2CYP1B1HSD17B3 | |
| SCHEMBL15842829 | 0.76 | MCL1 (0.58) | MCL1CYP1A1CYP1A2CYP1B1HSD17B3 | |
| SCHEMBL15842368 | 0.76 | MCL1 (0.54) | MCL1CYP1A1CYP1A2CYP1B1HSD17B3 | |
| SCHEMBL1771156 | 0.75 | KDM4E (0.77) | MCL1CYP1A1CYP1A2CYP1B1HSD17B3 | |
| SCHEMBL6525933 | 0.75 | L3MBTL1 (0.51) | CYP1A2MEN1ALDH1A1GAAHPGD | |
| SCHEMBL5760140 | 0.75 | MCL1 (0.47) | MCL1CYP1A1CYP1A2CYP1B1HSD17B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064207-B2 | 6-sulfonamido-quinolin-2-one and 6-sulfonamido-2-oxo-chromene derivatives, useful for treating alopecia, acne and oily skin | WARNER LAMBERT COMPANY LLC (US) | 2006-06-20 | — | — | US | disclosed |
| US-7009052-B2 | Sulfonamide derivatives | WARNER LAMBERT COMPANY LLC (US) | 2006-03-07 | — | — | US | disclosed |
| EP-1587804-A1 | ANDROGEN RECEPTOR ANTAGONISTS | Warner-Lambert Company LLC (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20050085467-A1 | Androgen receptor antagonists | DU DANIEL Y (US) | 2005-04-21 | — | — | US | disclosed |
| US-20050004367-A1 | Sulfonamide derivatives | DU DANIEL Y (US) | 2005-01-06 | — | — | US | disclosed |
| WO-2004065379-A1 | ANDROGEN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085467-A1 | Androgen receptor antagonists | AR, NR5A1, ESRRB | MCL1 4676/4885CYP1A1 370/4885CYP1A2 249/4885 |
| US-20050004367-A1 | Sulfonamide derivatives | AR, SULT2A1, SHBG | MCL1 4157/4885CYP1A1 285/4885CYP1A2 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.